=================== Social Forum Forum Thread GENTING BHD KLSE (MYR): GENTING (3182) ===================
Read the Forum thread title. Anything related to Genting Bhd KLSE 3182 can be discussed here including FA, TA, related news etc. Why want to control / restrict the topics being discussed?
@Michael you can also start a new forum thread:
<<GENTING BHD (FOR LONG TERM INVESTORS ONLY, TRADING DISCUSSIONS NOT WELCOME) >>
Im sure contributors there will abide by your rules.
terasa Genting is underperform because ppl gamble in Casino De Bursa instead of go Genting gambling Casino De Bursa got big advantage over Genting casino because Casino De Bursa is a halal casino where all races, all religion can gamble
ATK, it's your approach... we may not understand. You may consider yourself a mentor, guiding all the mentees, or perhaps sharing your experience could be a better approach? 😀
Posted by Michaelchan2024 > 1 hour ago | Report Abuse "I've already stated that I'm a long term investor, so I don't care where the share price moves in the short term..."
ATK, will there be a gap up tomorrow? We need your mentoring to trade TauRx news. --------------------
Aiya why you suddenly care abt where the share price moves in the short term? 旧'战国': 1) 4.20 - 4.00 - 5.00 2) 4.65 - 4.45 - 4.95 3) 4.95 - 4.55 - 4.87 新战国 4.87 - 4.65 - 5.10
We already have a stock guru with the crystal ball that can predict 5.10. Anything abt stock price movements better ask him la.
Stocks are approaching a 'watershed' moment as rate cuts unlock opportunity in unloved areas of the market, Wharton professor Jeremy Siegel says
Jul 29, 2024, 10:30 PM GMT+8
The stock market is about to see a major shift once the Fed cuts rates, Jeremy Siegel said.
The top economist thinks value stocks could start outperforming growth stocks once the Fed eases policy.
Cooling inflation data supports a Fed rate cut by September, Siegel predicted.
Stocks are about to reverse a long-running trend as rate cuts unlock an unsung area of the market, according to top economist Jeremy Siegel.
The Wharton School finance professor pointed to opportunity lurking in value stocks, an unloved group of the market that's underperformed this year when compared to growth stocks.
The S&P 500 Value index has climbed just 8% so far this year, according to S&P Global data. Those are far more muted returns than those seen in the S&P 500 Growth index, which has soared 20% from levels in January.
Growth stocks have outperformed partly due to Wall Street's AI craze, which has ignited investor fervor for growth stocks, like mega-cap tech firms.
But doubts are scaling over whether generative artificial intelligence is as revolutionary as investors originally priced in, Siegel said.
Meanwhile, the Fed looks poised to soon issue its first rate cut, which could unlock more movement on the market's value side, he predicted.
"You're not going to get value moving until the Fed drops rates, and more and more, when you see that rate drops are in the cards for the Fed, I think that narrative could very well continue," Siegel said in an interview with CNBC on Friday. "This really could be a watershed in terms of a trend we've seen for many many months, if not many years, of growth beating value."
Recent inflation data also makes the case for a soon-to-come Fed cut, Siegel said. The personal consumption expenditures price index, which is the Fed's preferred measure of inflation, continued to cool last month, fueling more hope that central bankers will soon ease up on monetary policy.
"Forward-looking, I think inflation looks very, very good," Siegel said, adding that an unexpectedly hot price reading wouldn't change the downward path of rates this year. "I don't think it changes the narrative of it at all that J. Powell is going to tee up a rate cut for the September meeting," he added.
Fed officials are set to convene this Tuesday and Wednesday to discuss their next policy move. Markets are pricing in a 96% chance the Fed will keep rates level on Wednesday but a 100% chance central bankers will cut rates at least 25 basis points by September, according to the CME FedWatch tool.
Jeremy Siegel has predicted that the stock market is about to see a major shift once the Fed cuts rates. He believes that value stocks, which have underperformed compared to growth stocks this year, could start outperforming once the Fed eases its policy. Siegel also mentioned that cooling inflation data supports the likelihood of a Fed rate cut by September.
Identified growth and value stocks:
1) Nvidia: Growth stock 2) Wynn Resorts: Value stock 3) Las Vegas Sands: Value stock 4) Genting Berhad: Value stock 5) Genting Malaysia: Value stock 6) YTL Power: Growth stock 7) YTL: Growth stock
When the MHRA has received your documents and validated them, we will contact to you within 5 working days to confirm that the 60-day assessment period has started, or we will let you know if there are any issues. If there are any issues raised, the 60-day assessment period will start when we receive a valid response.
Day 1 of the 60 days is taken as being the first day that follows the date of acceptance of a valid application. For example, if an application is received on 24 August and the assessor validates the submission on 28 August, the clock starts on 29 August.
During the assessment, experts will assess the safety and performance of your device as well as the design of the clinical investigation to be carried out. The MHRA will write to you if we require further information. It is essential that you contact the MHRA as soon as possible if you require clarification. If there are possible grounds for objection, where possible we will arrange a teleconference for a better understanding and to find a resolution within the 60-day assessment time.
A letter will be sent to you by the 60th day with a decision (‘objection’ or ‘no objection’) as to whether or not you can carry out the proposed clinical investigation.
Posted by Michaelchan2024 > 1 day ago | Report Abuse Accepted the initial application ..sahaja. Still long way to go Validation is the first step in the regulatory review process.. 看来ATK信心将大增 ------------
The main battle was already fought some time ago during the investment planning stage.
When the water is clear, there are no more fishes to catch.
I received Singapore PR around the age of 25 and was later informed by the government that I was exempted from NS. ATK, 放过我 lei.. Please don't ask further questions.
A lot of other experts here la. Let others share their advice. Little Taurx believers here anyway it could be just an illusion. If you think its 60 days, 150 days, etc no problem. Im not really bothered by when the approval because im a long term Taurx investor.
Posted by Michaelchan2024 > 2 days ago | Report Abuse
Based on the behavioral assessment, ATK is likely a TauRx shareholder. His behavior suggests a mix of insecurity and a strong need for approval and validation from others, which might stem from a lack of confidence in his own decisions. -------------
@Michael there is no need to analyse until paralyse la. After contributing numerous articles / news abt AD or Taurx and having said here that I hold some Taurx shares, anyone can easily conclude Im really holding some Taurx shares. Nothing special being a small Taurx shareholder la, there are over 1200 Taurx shareholders.
If Im not confident in my own trading / investment decisions, I wont be putting any money in them.
ATK is just a small fry compared to the real Musang King here in i3. When a person is cocky and self-confident (regardless of how good his skill is, even with 100% accuracy), he will invite insecure detractors to start all sorts of false accusations. Hence its a good idea to stay low profile.
ATK, I get your point. I wasn't trying to overanalyze or question your holdings. It's good to be confident in your decisions, and keeping a low profile can avoid unnecessary issues.
I usually only read detailed posts if they interest me or if I'm actively chatting here. Thanks for sharing your thoughts. 😀
Using Michael Porter’s Five Forces framework, if TauRx’s drugs were not thoroughly tested or failed to meet regulatory standards, they would not be classified as high quality pharmaceuticals. Instead, they would fall into the category of low quality alternatives, with all the associated risks and market implications.
Thus, the credibility of TauRx’s claims hinges on the rigour and transparency of their clinical trials and the subsequent regulatory approval. Without these, comparing their drugs to high quality, rigorously tested pharmaceuticals like the Pfizer COVID-19 vaccine would indeed be misleading.. 😀
This is not about low quality drugs.. if TauRx goes through the rigour and transparency of their clinical trials and subsequent regulatory approval. The point you highlighted above pertains to a different issue: the presence of counterfeit drugs.
Post a Comment
People who like this
New Topic
You should check in on some of those fields below.
Title
Category
Comment
Confirmation
Click Confirm to delete this Forum Thread and all the associated comments.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
Michaelchan2024
1,232 posts
Posted by Michaelchan2024 > 2024-07-29 19:20 | Report Abuse
Validation is the first step in the regulatory review process.. 看来ATK信心将大增